Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03653338 · ClinicalTrials.gov registry record · Phase 1
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
A Phase 1 study of Sickle Cell Anemia and Diamond-Blackfan Anemia, sponsored by Paul Szabolcs.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT03653338 is a Phase 1 study of Sickle Cell Anemia and Diamond-Blackfan Anemia that is actively recruiting participants, run by Paul Szabolcs. The registered enrollment target is 5 participants, below the 100-participant average among 22 other Sickle Cell Anemia trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03653338, a Phase 1 study of Sickle Cell Anemia and Diamond-Blackfan Anemia, is actively recruiting participants, sponsored by Paul Szabolcs.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate what effect, if any, mismatched unrelated volunteer donor and/or haploidentical related donor stem cell transplant may have on severe sickle cell disease and other transfusion dependent anemias. By using mismatched unrelated volunteer donor and/or haploidentical related donor stem cells, this study will increase the number of patients who can undergo a stem cell transplant for their specified disease. Additionally, using a T-cell depleted approach should reduce the incidence of graft-versus-host disease which would otherwise be increased in a mismatched transplant setting.
Conditions Studied
Interventions
- DRUG Alemtuzumab
- DRUG Hydroxyurea
- DRUG Rituximab
- BIOLOGICAL CD3/CD19 depleted leukocytes
- BIOLOGICAL CD45RA depleted leukocytes
Study Locations (1)
Pennsylvania
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-08-02 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03653338
The ClinicalTrials.gov registry entry for NCT03653338 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100-participant average among 22 other Sickle Cell Anemia trials with a reported enrollment target (95% lower). The listed sponsor is Paul Szabolcs, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sickle Cell Anemia appearing as the primary indexed condition, and to 5 interventions - of which Alemtuzumab is the first listed.
NCT03653338 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03653338 about?
NCT03653338 is a clinical study titled "T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias". The purpose of this study is to evaluate what effect, if any, mismatched unrelated volunteer donor and/or haploidentical related donor stem cell transplant may have on severe sickle cell disease and other transfusion dependent anemias. By using mismatched unrelated volunteer donor and/or haploidenti...
What is the current status of trial NCT03653338?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2018-08-02. Estimated completion is 2027-08-01.
What conditions does trial NCT03653338 study?
This clinical trial studies the following conditions: Sickle Cell Anemia, Diamond-Blackfan Anemia, Beta-thalassemia Major.
What interventions are being tested in trial NCT03653338?
The interventions under investigation include: Alemtuzumab (DRUG), Hydroxyurea (DRUG), Rituximab (DRUG), CD3/CD19 depleted leukocytes (BIOLOGICAL), CD45RA depleted leukocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT03653338?
This trial is sponsored by Paul Szabolcs, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03653338 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Haploidentical PBMC Transplant for Severe Congenital Anemias
ACTIVE NOT RECRUITING · Phase 1
-
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
ACTIVE NOT RECRUITING · Phase 1
-
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
COMPLETED · Phase 1
-
Nitric Oxide and Transfusion Therapy for Sickle Cell Patients With Pulmonary Hypertension
COMPLETED · Phase 1
-
Hematopoietic Stem Cell Transplant for Sickle Cell Disease
COMPLETED · Phase 1
-
Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.